CU Cancer Center Member Highlights Long-Term Survival Benefits of Liso-Cel in R/R LBCL

Manali Kamdar, MD, reviews long-term follow-up data from the TRANSFORM trial showing durable overall survival with lisocabtagene maraleucel in second-line R/R LBCL.